Pregabalin Capsule
Product Images NDC 71610-792

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-792). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0792 30)

Pregabalin 25 mg oral capsules package label. The label indicates a 30-capsule carton with storage instructions to keep between 60-77 degrees Fahrenheit. The label shows the NDC number 71510-0792-30, manufacturer MSN Laboratories Private Limited, and repackager Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. Additional labeling includes warnings about habit forming and labeling for Rx only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

A formula panel showing the calculation for creatinine clearance (CLCr) based on age, weight, and serum creatinine levels, with an adjustment factor of 0.85 for female patients. The formula is presented as a fraction with numerator and denominator components.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 25 mg, 100 mg, and 200 mg three times a day against placebo. The y-axis represents percent of patients improved, and the x-axis shows percent improvement in pain from baseline, illustrating differences in patient response across the four groups.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier-like curve graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares two groups: one receiving Pregabalin 100 mg three times a day (dashed line) and a placebo group (dotted line). The graph illustrates patient response rates across various percentages of pain improvement.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin taken orally at doses of 75 mg, 150 mg, and 300 mg, each administered two times a day, compared to placebo. The graph depicts multiple curves corresponding to different dosages and placebo across a range of pain improvement percentages from 0 to 100.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line). The data illustrates trends in pain improvement across different percentages for each group.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. The chart compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The x-axis represents percent improvement in pain from baseline (0 to 100), and the y-axis represents percent of patients improved (0 to 100).*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

Bar chart showing Responder Rate (%) in Studies E1 and E3 for varying daily doses of Pregabalin compared to placebo. Study E1 includes placebo and 50 mg, 150 mg, 300 mg, 600 mg per day doses with BID dosing, while Study E3 includes placebo and 600 mg per day doses with BID and TID dosing. Each bar shows the responder rate percentage and sample size (N) for each group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day. Four dosing regimens are plotted: Stukly E1BID, E2BID, E3BID, and E3TID, each represented by different symbols. Significant p-values less than or equal to 0.0001 are indicated at multiple dose points, demonstrating increased seizure reduction with higher doses up to 600 mg/day. Placebo corresponds to 0 dose.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A Kaplan-Meier style line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for oral Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, compared to placebo. The x-axis shows percent improvement in pain from baseline (0 to 100), and the y-axis shows percent of patients improved (0 to 100%). Four curves represent different treatment groups with labels for each dose and placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart comparing Pregabalin and placebo groups over 180 days, showing the estimated percentage of subjects without LTR (loss to response) on the y-axis and time in days on the x-axis. The solid line represents Pregabalin, and the dashed line represents placebo.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 12 using a BOCF method, with two lines representing Pregabalin and Placebo groups. The vertical axis shows percent of subjects improved, ranging from 0 to 100, and the horizontal axis shows percent improved from baseline to week 12 in increments from >0 to ≥100.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This figure is a cumulative distribution plot showing the percent of subjects improved on the vertical axis versus percent improvement from baseline to week 16 on the horizontal axis. Two lines compare Pregabalin and Placebo groups, with Pregabalin showing a consistently higher percentage of subjects improved across the range of improvements.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure diagram of Pregabalin showing its molecular configuration with labeled functional groups including an amine (NH2), a carboxyl group (COOH), and methyl side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.